entertainment -WSS

entertainment

author：focus 2025-09-03 14:42:12 - browse：379

The New York Stock Exchange (NYSE) — Spencer Platt/Getty Images

Biohaven Pharmaceuticals said Wednesday that a new type of experimental medicine reduced levels of a disease-causing immune molecule by up to 37% in an early-stage study of human volunteers — a result that the company called “positive” as a proof of concept but that also fell short of investor expectations.

The drug, called BHV-1300, belongs to a new class of antibody medicines that shuttle harmful proteins to the liver so they can be removed from the body. BHV-1300 is specifically designed to reduce levels of an autoantibody called IgG that is implicated in rheumatoid arthritis, myasthenia gravis, and other autoimmune disorders.

In its Phase 1 study, Biohaven tested four escalating doses of BHV-1300 in healthy volunteers, showing a reduction in levels of IgG of 5%, 15%, 30%, and 37%, respectively, the company said. The reductions in IgG levels, which occurred relatively quickly in just four to five days, did not cause significant, adverse changes in liver enzyme levels, Biohaven added — an important safety check given the mechanism of the drug.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Illumina board agrees to spin off Grail, as divestment plans proceed

WSS

Fight over Supreme Court dialysis ruling puts kidney patients at risk

For pregnant people, addiction treatment shouldn't mean a call to child protective services

Study gives hint on South Asians’ higher risk of cardiovascular disease

STAT Boddities: What happens to the brain when we get scared?

Latigo launches with $135 million for Vertex

AMAs digital advisors table RPM coding reform proposal, again

explore

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Jerome Adams on the need for new antivirals for Covid

For pregnant people, addiction treatment shouldn't mean a call to child protective services

Bright Health sells Medicare Advantage business to Molina

'Little Tech' descents on D.C., wanting a say in how AI is regulated

Moonlake's readout produced a cash windfall. Risks remain

STAT Boddities: What happens to the brain when we get scared?

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Abbott's new heart device gets FDA advisory panel nod

Walensky prepares to leave CDC — and Congress — behind

Data don't support strong claims for Covid

knowledge

Fight over Supreme Court dialysis ruling puts kidney patients at risk

Data don't support strong claims for Covid

Anthony Fauci pushes back on GOP claims during Covid hearing

Novartis is flashing warning signs about its newly acquired myelofibrosis drug

For pregnant people, addiction treatment shouldn't mean a call to child protective services

AMAs digital advisors table RPM coding reform proposal, again

focus

hotspot

entertainment

entertainment